BioSpace News Archive

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Integumen plc to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of the coronavirus in waste water, to provide a real-time alert system to warn of localised COVID-19 outbreaks.

Fifty-seven year old dialysis patient Tracey Amadi of central New Jersey is the first person in the world to use Outset Medical’s mobile Tablo Hemodialysis System at home since it received FDA clearance on March 31.

NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced that it has completed an underwritten public offering with gross proceeds of $11.5 million before deducting underwriting discounts and other estimated offering expenses.

Intended use allows gammaCore Sapphire CV use at home or in a healthcare setting

Mateon Therapeutics, a leading developer of TGF-β therapeutics, announced that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.

Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC

MINNEAPOLIS, July 13, 2020 Bio-Techne Corporation announced that management will host a conference call and webcast on Tuesday, August 4, 2020, at 8:00 a.m. CDT to review fourth quarter 2020 financial results.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX.V: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced the identification of additional, human lead candidate antibodies generated against SARS-CoV-2,

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides perspectives on the planned clinical trial testing of Brilacidin, administered intravenously (IV), for the treatment of COVID-19. The exigencies of the pandemic coupled with Brilacidin’s multiple therapeutic properties – its anti-viral SARS-CoV-2 activity, its anti-inflammatory potential to abate the COVID-19 associated cytokine

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”), announced that today Chief Executive Officer Michael Poirier has issued a letter to Qualigen’s stockholders. The full text of that letter is as follows: To My Fellow Stockholders, Many of you likely saw last week’s exciting announcement that Qualigen